THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Naoko Takebe to Prostatic Neoplasms, Castration-Resistant

Back to Details
This is a "connection" page, showing publications Naoko Takebe has written about Prostatic Neoplasms, Castration-Resistant.
Naoko Takebe
Connection Strength
0.112
Prostatic Neoplasms, Castration-Resistant
  1. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 Oct; 32(5):1005-16.
    View in: PubMed
    Score: 0.112
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES